Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 4/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108522 | 0.85 | NPC1 (0.53) | HCAR3AURKAAURKBNPC1RAB9A | |
| SCHEMBL4876776 | 0.85 | NPC1 (0.53) | HCAR3AURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10837371 | 0.85 | ROCK1 (0.59) | HCAR3AURKAAURKBNPC1RAB9A | |
| SCHEMBL30828593 | 0.83 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13685582 | 0.82 | — | — | |
| SCHEMBL7105114 | 0.82 | NPC1 (0.63) | HCAR3AURKAAURKBNPC1RAB9A | |
| SCHEMBL6093171 | 0.82 | NPC1 (0.68) | AURKANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30073949 | 0.82 | NPC1 (0.63) | HCAR3AURKAAURKBNPC1RAB9A | |
| SCHEMBL29582475 | 0.81 | MEN1 (0.64) | HCAR3AURKAAURKBNPC1RAB9A | |
| SCHEMBL626575 | 0.81 | MEN1 (0.64) | HCAR3AURKAAURKBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102180942-A | Preparation method of moguisteine intermediate 17 beta-hydroxyl-4 alpha, 5 alpha-epoxy androstane (2,3-d) isoxazole | TIANJIN KILO PHARMACEUTICAL SCI TECH CO LTD | 2011-09-14 | — | — | CN | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| WO-2007144379-A1 | BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS | MEDIVIR AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144379-A1 | BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS | MEDIVIR AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0098951-A2 | Aminobenzamide derivatives and preparation thereof | STERLING DRUG INC. (US) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | HCAR3 1278/4885AURKA 4299/4885AURKB 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.